These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 20015152)
41. Interferon-α induced lupus in a patient with chronic hepatitis C virus. Rizvi R; Hojjati M J Clin Rheumatol; 2011 Apr; 17(3):152-3. PubMed ID: 21441813 [No Abstract] [Full Text] [Related]
42. Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery. Morimoto K; Yamagami H; Hosomi S; Ohira M; Suekane T; Kamata N; Sogawa M; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Tamori A; Oshitani N; Arakawa T Am J Gastroenterol; 2009 Jun; 104(6):1609-10. PubMed ID: 19491886 [No Abstract] [Full Text] [Related]
43. Interferon for hepatitis C patients with psychiatric disorders. Asnis GM; De La Garza R; Rego SA; Henderson MA; Reinus JF Am J Psychiatry; 2004 Dec; 161(12):2332; author reply 2332-4. PubMed ID: 15569920 [No Abstract] [Full Text] [Related]
44. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Grossmann Sde M; Teixeira R; de Aguiar MC; do Carmo MA Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):702-6. PubMed ID: 18679075 [TBL] [Abstract][Full Text] [Related]
45. Hepatitis C virus therapy to date. Foster G; Mathurin P Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157 [TBL] [Abstract][Full Text] [Related]
47. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection. Keam SJ; Cvetković RS BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193 [TBL] [Abstract][Full Text] [Related]
48. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection]. Lee MY; Cho H; Kim YM; Lee JS Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297 [TBL] [Abstract][Full Text] [Related]
49. [Patient with HCV chronic hepatitis who has subcutaneous nodules after finishing treatment with pegylated interferon]. Salgado Ordóñez F; Manteca González R; Palacios Rodríguez S; Godoy Guerrero M Rev Clin Esp; 2005 Dec; 205(12):621-2. PubMed ID: 16527184 [No Abstract] [Full Text] [Related]
50. Development of sarcoidosis in cosmetic tattoos. Antonovich DD; Callen JP Arch Dermatol; 2005 Jul; 141(7):869-72. PubMed ID: 16027303 [TBL] [Abstract][Full Text] [Related]
51. Pernicious anemia during peginterferon-alpha2b plus ribavirin therapy for chronic hepatitis C. Musialik J; Petelenz M; Błoñska-Fajfrowska B; Hartleb M Eur J Gastroenterol Hepatol; 2009 May; 21(5):593-4. PubMed ID: 19194303 [No Abstract] [Full Text] [Related]
52. Cutaneous sarcoidosis limited to scars following pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C. Perez-Gala S; Delgado-Jimenez Y; Goiriz R; Fernandez-Herrera J; Fraga J; Garcia-Diez A J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):393-4. PubMed ID: 17309467 [No Abstract] [Full Text] [Related]
53. [Management of sarcoidosis-associated chronic hepatitis C virus infection: course and treatment]. Longueira Suárez R; Ammari I; Lamas Ferreiro JL; Sopeña Pérez-Argüelles B; Martínez-Vázquez C Rev Clin Esp; 2009; 209(7):358-9. PubMed ID: 19709544 [No Abstract] [Full Text] [Related]
54. Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C. Njouom R; Sartre MT; Timba I; Nerrienet E; Tchendjou P; Pasquier C; Rousset D J Med Virol; 2008 Dec; 80(12):2079-85. PubMed ID: 19040282 [TBL] [Abstract][Full Text] [Related]
55. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients. Taylor LE; Rich JD; Tashima KT N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553 [No Abstract] [Full Text] [Related]
56. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice. Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928 [TBL] [Abstract][Full Text] [Related]
57. Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient. Wang BY; Chang HH; Chen IM; Shih CC; Yang AH Ann Thorac Surg; 2010 May; 89(5):1645-7. PubMed ID: 20417802 [TBL] [Abstract][Full Text] [Related]
58. Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency. Demelia L; Civolani A; Murgia D; Murru A; Sorbello O; Rizzetto M J Hepatol; 2007 Jan; 46(1):171-3. PubMed ID: 17107736 [No Abstract] [Full Text] [Related]
59. Hepatitis C treatment, HAART and side effects. TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865 [No Abstract] [Full Text] [Related]
60. [Antiviral therapy in a patient with chronic hepatitis C, metabolic syndrome and interferon-induced depression]. Baĭzhanova ZhZh; Ignatova TM; Kinkul'kina MA Klin Med (Mosk); 2010; 88(6):65-7. PubMed ID: 21395034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]